VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD

10 апр 2023 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

07 мар 2023 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update

21 фев 2023 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD

20 дек 2022 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD

19 дек 2022 16:01:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update

09 ноя 2022 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces November 2022 Investor Conference Participation

02 ноя 2022 03:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update

26 окт 2022 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance

17 окт 2022 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD

14 окт 2022 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

29 авг 2022 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma strengthens commercialization leadership team

24 авг 2022 02:00:00 Источник Nasdaq GlobeNewswire

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

19 авг 2022 02:46:07 Источник Nasdaq GlobeNewswire

Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs

15 авг 2022 16:05:00 Источник Nasdaq GlobeNewswire

Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering

10 авг 2022 20:22:20 Источник Nasdaq GlobeNewswire

Verona Pharma plc Announces Proposed Underwritten Public Offering

09 авг 2022 16:16:44 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update

09 авг 2022 03:01:03 Источник Nasdaq GlobeNewswire

Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD

09 авг 2022 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD

08 авг 2022 16:30:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update

29 июл 2022 02:00:00 Источник Nasdaq GlobeNewswire